( SAN CARLOS Calif. April 04 2007 /PR...)Nuvelo Announces Presentation on NU206 at 2007 American Association,for Cancer Research Annual Meeting,Health

SAN CARLOS, Calif., April 04, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that preclinical data evaluating the mechanism of action and role of NU206 (R-Spondin1) as a specific and potent stimulator of the gastrointestinal (GI) epithelial cells will be presented in an educational session at the 2007 American Association for Cancer Research (AACR) Annual Meeting taking place at the Los Angeles Convention Center in Los Angeles, CA, April 14-18, 2007.

    The presentation details are as follows:

          Date/Time: Saturday, April 14, 2007, 8:00-10:00 a.m. PDT

          Location: Room 403 A-B, Los Angeles Convention Center

          Session/Abstract Title: Therapeutic Cancer Targets in the Wnt

          Pathway/R-Spondin, novel regulators of the Wnt/b-catenin signaling


    About NU206

NU206, also known as human R-spondin1, is a recombinant, secreted protein that has the potential to act as a potent and highly specific growth factor of GI epithelial cells. In early animal model studies, NU206 promoted growth and repair of these tissues in models of radiation treatment or chemotherapy, as well as in animal models of inflammatory bowel disease and short bowel syndrome. A publication in the August 2005 issue of Science described results from studies in animal models of mucositis, where NU206 was shown to diminish symptoms of mucositis, including diarrhea and weight loss.

About Nuvelo and Kirin's Joint Collaborative Effort

Scientists from Nuvelo and Kirin worked together to identify and characterize NU206 as part of a collaboration focused on the discovery of novel, secreted proteins. NU206 is the first compound to enter preclinical studies from this program. Nuvelo signed a collaboration agreement with Kirin in April 2005 to develop NU206. Under the agreement, Nuvelo leads worldwide development, manufacturing and commercialization and all operating expenses and p
'"/>